Fulgent Genetics Stock Earnings Per Share
| FLGT Stock | USD 20.11 0.02 0.1% |
Fulgent Genetics fundamentals help investors to digest information that contributes to Fulgent Genetics' financial success or failures. It also enables traders to predict the movement of Fulgent Stock. The fundamental analysis module provides a way to measure Fulgent Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fulgent Genetics stock.
Fulgent | Earnings Per Share |
Fulgent Genetics Company Earnings Per Share Analysis
Fulgent Genetics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Fulgent Genetics Earnings Per Share | (5.63) X |
Most of Fulgent Genetics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulgent Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Fulgent Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Fulgent Genetics is extremely important. It helps to project a fair market value of Fulgent Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Fulgent Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fulgent Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fulgent Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Fulgent Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Fulgent Genetics has an Earnings Per Share of -5.63 times. This is 167.26% lower than that of the Health Care Providers & Services sector and notably lower than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
Fulgent Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulgent Genetics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics of similar companies.Fulgent Genetics is currently under evaluation in earnings per share category among related companies.
Fulgent Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0347 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 185 M | ||||
| Shares Outstanding | 29.9 M | ||||
| Shares Owned By Insiders | 32.58 % | ||||
| Shares Owned By Institutions | 49.31 % | ||||
| Number Of Shares Shorted | 603.98 K | ||||
| Price To Earning | 3.95 X | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 2.15 X | ||||
| Revenue | 289.21 M | ||||
| Gross Profit | 366.9 M | ||||
| EBITDA | (43.54 M) | ||||
| Net Income | (167.82 M) | ||||
| Cash And Equivalents | 515.4 M | ||||
| Cash Per Share | 17.03 X | ||||
| Total Debt | 14.91 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 38.31 X | ||||
| Cash Flow From Operations | 27 M | ||||
| Short Ratio | 2.23 X | ||||
| Earnings Per Share | (5.63) X | ||||
| Price To Earnings To Growth | 1.32 X | ||||
| Target Price | 26.67 | ||||
| Number Of Employees | 1.18 K | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 601.3 M | ||||
| Total Asset | 1.27 B | ||||
| Retained Earnings | 633.17 M | ||||
| Working Capital | 434.83 M | ||||
| Current Asset | 2.93 M | ||||
| Current Liabilities | 686 K | ||||
| Net Asset | 1.27 B |
About Fulgent Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulgent Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fulgent Genetics Piotroski F Score and Fulgent Genetics Altman Z Score analysis. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stocks Directory Find actively traded stocks across global markets |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.